Xeris pharmaceuticals, inc. (XERS)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17Jun'17
Net sales

1,700

-

-

-

0

-

-

-

-

-

-

Grant and other income

112

219

314

314

248

812

582

819

210

170

549

Cost of goods sold

1,790

-

-

-

0

-

-

-

-

-

-

Service revenue

-

-

9

6

-

-

0

0

53

0

16

Cost of revenue

-

-

10

23

-

-

0

0

42

0

4

Gross profit (loss)

-2

261

313

297

248

801

582

819

221

170

561

Operating expenses
Research and development

6,646

12,420

15,518

19,333

13,167

12,390

10,875

8,677

8,712

5,725

4,201

Selling, general and administrative

21,606

20,642

14,877

15,024

12,518

-

4,650

4,499

-

-

-

Selling, general and administrative

-

-

-

-

-

-

-

-

3,239

2,017

1,559

Total operating expenses

28,252

33,062

30,395

34,357

25,685

21,115

15,525

13,176

11,951

7,742

5,760

Loss from operations

-28,254

-32,801

-30,082

-34,060

-25,437

-20,314

-14,943

-12,357

-11,730

-7,572

-5,199

Other income (expense)
Interest and other income

434

640

657

845

671

817

462

238

96

45

0

Interest expense

-1,500

12,832

-3,507

-1,062

-1,100

3,990

-737

-562

-191

0

-1

Change in fair value of warrants

135

-1,232

96

-108

552

-259

451

-306

-82

0

-32

Other expense

-

-

-

-

-

-

-

-

-

-

-33

Total other income (expense)

-930

-739

-2,754

-325

160

-105

176

-630

-177

45

-

Net loss before provision for/benefit from income taxes

-29,184

-

-

-

-25,277

-

-

-

-

-

-

Provision for/benefit from income taxes

0

-

-

-

0

-

-

-

-

-

-

Net loss

-29,184

-33,082

-32,836

-34,385

-25,277

-20,419

-14,767

-12,987

-11,907

-7,527

-5,232

Other comprehensive income (loss), net of tax
Unrealized gains on investments

49

-

-

-

51

-

-

-

-

-

-

Foreign currency translation adjustments

-32

-

-

-

0

-

-

-

-

-

-

Unrealized gains (losses) on investments

-

-

-23

69

-

-

-58

0

0

0

-

Comprehensive loss

-29,167

-33,084

-32,859

-34,316

-25,226

-20,413

-14,825

-12,987

-11,907

-7,527

-

Net loss per common share - basic and diluted

-0.89

-1.24

-1.22

-1.28

-1.07

4.28

-0.71

-3.07

-5.49

-3.72

-2.59

Weighted average common shares outstanding, basic and diluted

32,790

27,048

26,942

26,889

23,561

21,068

20,714

4,231

2,169

2,024

2,022